Original Article
Imipramine in Patients with Chest Pain Despite Normal Coronary Angiograms
N Engl J Med 1994; 330:1411-1417May 19, 1994
- Abstract
Background
Ten to 30 percent of patients undergoing cardiac catheterization because of chest pain are found to have normal coronary angiograms. Because these patients may have a visceral pain syndrome unrelated to myocardial ischemia, we investigated whether drugs that are useful in chronic pain syndromes might also be beneficial in such patients.
Methods
Sixty consecutive patients underwent cardiac, esophageal, psychiatric, and pain-sensitivity testing and then participated in a randomized, double-blind, placebo-controlled three-week trial of clonidine at a dose of 0.1 mg twice daily (20 patients), imipramine at a dose of 50 mg nightly with a morning placebo (20 patients), or placebo twice daily (20 patients); this treatment phase was compared with an identical period of twice-daily placebo for all patients (placebo phase).
Results
Thirteen (22 percent) of the 60 patients had ischemic-appearing electrocardiographic responses to exercise, 22 of the 54 tested (41 percent) had abnormal esophageal motility, 38 of 60 (63 percent) had one or more psychiatric disorders, and 52 of 60 (87 percent) had their characteristic chest pain provoked by right ventricular electrical stimulation or intracoronary infusion of adenosine. During the treatment phase, the imipramine group had a mean (±SD) reduction of 52 ±25 percent in episodes of chest pain, the clonidine group had a reduction of 39 ±51 percent, and the placebo group a reduction of 1 ±86 percent, all as compared with the placebo phase of the trial. Only the improvement with imipramine was statistically significant (P = 0.03). Repeat assessment of sensitivity to cardiac pain while the patients were receiving treatment showed significant improvement only in the imipramine group (P = 0.01). The response to imipramine did not depend on the results of cardiac, esophageal, or psychiatric testing at base line, or on the change in the psychiatric profile during the course of the study, which generally improved in all three study groups.
Conclusions
Imipramine improved the symptoms of patients with chest pain and normal coronary angiograms, possibly through a visceral analgesic effect.
Media in This Article
Figure 1
Percent Change in the Frequency of Chest Pain from the Placebo Phase to the Treatment Phase in Patients with Abnormal and Normal Results on Base-Line Cardiac, Esophageal, and Psychiatric Testing, According to Treatment Group.Figure 2
Patients with Chest Pain during Right Ventricular Stimulation at Base Line and during the Treatment Phase, According to Treatment Group.Article Activity
- Article
Ten to 30 percent of patients with chest pain sufficiently similar to angina to justify cardiac catheterization are found to have normal coronary angiograms1-6. Despite a good prognosis and the beneficial effect of reassurance for many patients, most continue to have chest pain that may result in visits to the emergency room, admission to the coronary care unit, and even repeat cardiac catheterization1-5,7-9. Thus, an apparently benign condition may have considerable adverse effects on the quality of life, employment, and the use of health care resources, with the attendant expenses.
Several possible causes of chest pain in such patients have been proposed, including psychiatric illness,10-13 esophageal dysfunction,14-17 and coronary microvascular dysfunction18-22; overlap among these conditions has also been reported23-25. Recently, several groups of investigators have described exaggerated sensitivity to cardiac26-28 and esophageal25,29 pain in patients who have chest pain despite normal coronary angiograms. We conducted a study to categorize the cardiac, gastrointestinal, and psychiatric findings and the results of pain-sensitivity testing in a consecutive series of patients who had chest pain despite normal coronary angiograms. We also assessed the effect of imipramine and clonidine -- drugs that have been used successfully in the management of chronic pain syndromes -- in the same patients in a randomized, double-blind, placebo-controlled trial.
Methods
Patients
We studied 60 consecutive patients who met the following entry criteria: normal coronary angiograms and no epicardial coronary-artery spasm after the intravenous administration of ergonovine (0.15 mg), normal left ventricular function at rest, no evidence of left ventricular hypertrophy or valvular heart disease (including mitral-valve prolapse) on echocardiography, blood pressure no higher than 160/100 mm Hg when they were receiving no medications, and no musculoskeletal sensitivity that accounted for their characteristic chest pain. All the patients had been referred to the National Institutes of Health because of recurrent chest pain; we made no attempt to select patients for the study on the basis of the results of any previous testing. Fifty-seven patients had previously been given antiischemic therapy (calcium-channel blockers, beta-blockers, or nitrates), which had failed to control their symptoms; the remaining three patients were untreated. All the patients discontinued all medications except estrogen replacement (15 patients), thyroid hormone replacement (6 patients), and insulin (2 patients) for at least one week before admission. This study was approved by the National Heart, Lung, and Blood Institute Review Board, and informed consent was obtained from all patients.
Base-Line Studies
All patients underwent symptom-limited treadmill exercise testing using the standard Bruce protocol30 and gated blood-pool scanning with technetium-99m radionuclide angiography both at rest and during exercise31. After an overnight fast and the ingestion of 10 mg of diazepam, all patients underwent cardiac catheterization, during which a 6-French pacing wire was advanced to the apex of the right ventricle. Pacing was then initiated without the patient's awareness at a rate 5 beats per minute faster than the resting heart rate, with the stimulus intensity starting at 1 mA and increasing by 1-mA increments at 10-second intervals to 10 mA. Adenosine (2.2 mg per minute for two minutes) was later infused into the left coronary artery of 57 patients. If chest pain was reported during either test, the patients were asked whether this pain was the same as their characteristic chest pain.
After an overnight fast and anesthesia with topical lidocaine, patients underwent testing of esophageal motility and modified Bernstein testing, as described previously25. To assess esophageal sensitivity, a polyvinyl balloon was inflated 6 to 8 cm proximal to the catheter tip with 1-ml increments of air until the patient had chest pain or the balloon reached a diameter of 30 mm. The test was interpreted as positive if balloon distention precipitated the patient's characteristic chest pain. All patients were interviewed by the same psychiatric nurse using the Schedule for Affective Disorders and Schizophrenia -- Lifetime Version, modified for the study of anxiety disorders32,33. Because chest pain was a criterion for participation in this study, this symptom was not used for the diagnosis of panic disorder. Responses to the diagnostic interview were reviewed by the nurse interviewer and two research psychiatrists, and psychiatric diagnoses were determined according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, third edition, revised (DSM-III-R)34. Eleven standardized rating scales for psychiatric symptoms and functional impairment were also administered35-38.
Placebo-Controlled Trial
Placebo Phase
Because we expected that there would be substantial response to placebo in a group of patients with a chronic pain syndrome who had recently undergone an extensive evaluation and who had been reassured about the benign nature of their symptoms, we initially treated all patients with single-blind placebo. The response to subsequent double-blind active treatment could then be compared with the effect of placebo, if any. Accordingly, after the completion of the base-line testing, all patients were discharged with directions to take medication (placebo) twice daily (at 9 a.m. and 9 p.m.) for five weeks. All the patients were issued a symptom diary and were instructed to record each episode of chest pain they experienced. Patients were also instructed to rate the average intensity of chest pain for each day by choosing 1 of 13 terms, ranging from “no pain” to “extremely intense pain.” The relative magnitude of pain was quantified on a logarithmic scale and averaged for each week39,40. All the patients returned to the clinical center during the fifth week of the placebo phase, at which time their diaries and ratings of the intensity of chest pain were collected and inspected for compliance. All the patients underwent psychiatric interviews while continuing to take the placebo.
Treatment Phase
All the patients were then randomly assigned in a double-blind fashion to one of three treatment groups: imipramine (25 mg at 9 p.m. for one week, then 50 mg nightly thereafter, always with a matching placebo at 9 a.m.), clonidine (0.05 mg at 9 a.m. and 9 p.m. for one week, then 0.1 mg for both doses thereafter), or placebo at 9 a.m. and 9 p.m. Thus, patients took the full dose of treatment for three weeks (weeks 2 through 4) before returning to the clinical center. All capsules for the single-blind placebo phase and the double-blind treatment phase were identical in appearance. During the fifth week of the treatment phase, all the patients returned and their symptom diaries and ratings of chest-pain intensity were collected. While treatment continued, they underwent testing of sensitivity to cardiac pain, testing of esophageal motility, balloon-distention testing of pain sensitivity, and a psychiatric interview. During this double-blind treatment phase, all tests and analyses were performed by personnel without knowledge of the patients' treatment assignment.
Statistical Analysis
Data are presented as means ±SD. Because patients received the full dose of imipramine, clonidine, or placebo during weeks 2 through 4, before returning to the clinical center, we analyzed the frequency of chest pain during these three weeks of the treatment phase and compared the results with the frequency of pain during the corresponding three weeks of the placebo phase. The changes in the frequency of chest pain, ratings of the intensity of chest pain, and responses to psychiatric testing from the placebo phase to the treatment phase (and, for psychiatric testing, from base line to the treatment phase) were compared for the three treatment groups by repeated-measures two-way analysis of variance with assessment of possible interactions between drug and time or drug and diagnosis41. If statistical significance was identified (indicated by a two-tailed P<0.05), intergroup comparisons were performed with Bonferroni's or Dunnett's test to assess the relative effect of the three treatments41. Furthermore, if a statistically significant interaction between drug and diagnosis was found, stratified analyses comparing normal patients and those with abnormal conditions were performed for each treatment group. The results of testing for sensitivity to cardiac and esophageal pain at base line and during the treatment phase were analyzed with an exact binomial test. Categorical data were compared by chi-square analysis.
Results
Of the 60 patients enrolled in the study, 40 were women and 20 were men. The average age was 50 years (range, 29 to 72). The duration of chest-pain symptoms averaged 53 months (range, 3 to 175). Forty-one patients (68 percent) had been hospitalized for chest pain, excluding hospitalizations for the initial cardiac catheterization and the evaluation at the National Institutes of Health, and 30 patients (50 percent) had been hospitalized for chest pain more than once (range, 2 to 25 additional hospitalizations). Twenty-nine patients (48 percent) had been hospitalized for chest pain despite having had normal coronary arteries on angiography during a prior hospitalization (range, 1 to 14 hospitalizations). Eighteen patients (30 percent) had undergone more than one cardiac catheterization before their evaluation at the National Institutes of Health (range, two to nine additional cardiac-catheterization procedures). The clinical characteristics of the patients at randomization are presented in Table 1Table 1
Clinical Characteristics of the Study Population, According to Treatment Group.; there were no substantive differences among the groups.Base-Line Testing
Twenty-three patients (38 percent) had one or more abnormalities on exercise testing (defined as a horizontal or downsloping ST-segment depression of more than 1 mm on the electrocardiogram, bundle-branch-block pattern on the electrocardiogram, decrease in the left ventricular ejection fraction, or wall-motion abnormality). Of these, 13 patients had electrocardiographic responses to exercise associated with chest pain that were similar to that caused by ischemia, commonly designated as syndrome X22.
During cardiac catheterization, 47 patients (78 percent) had chest pain during right ventricular pacing at a rate 5 beats faster than their resting heart rate (median stimulus intensity at onset of pain, 3 mA); 40 of these 47 (85 percent) considered it their characteristic chest pain. During the infusion of adenosine in 57 patients, 54 patients (95 percent) had chest pain, in all cases without electrocardiographic changes characteristic of ischemia; 47 (87 percent) considered it their characteristic chest pain. Overall, the characteristic chest pain was provoked in 52 of 60 patients (87 percent) by either right ventricular pacing or the intracoronary infusion of adenosine.
Fifty-four patients (90 percent) underwent esophageal testing; the remaining six patients were unable to tolerate the motility-testing catheter. Twenty-two of the 54 patients tested (41 percent) met the criteria for a motility disorder (distal high-amplitude peristalsis, 12 patients; nonspecific motility disorder, 10 patients) and 22 (41 percent) had their characteristic chest pain provoked by the administration of edrophonium, the infusion of hydrochloric acid (Bernstein test), intraesophageal balloon distention, or more than one of these tests. Thirty-eight patients (63 percent) had fulfilled DSM-III-R criteria for one or more psychiatric diagnoses at some time during their lives; these were panic disorder (with chest pain excluded as a diagnostic criterion) in 26 patients, a history of major depression in 17, somatization in 11, current major depression in 3, hypochondriasis in 2, alcohol dependence in 2, other anxiety disorders in 5, and other non-anxiety diagnoses in 7. Patients with psychiatric diagnoses at any time during their lives were no more likely to have esophageal dysmotility (41 percent), esophageal pain sensitivity (38 percent), or cardiac pain sensitivity (87 percent) than patients without psychiatric diagnoses (40 percent, 45 percent, and 86 percent, respectively). There were no significant differences in the results of base-line cardiac, esophageal, or psychiatric testing among the treatment groups (Table 2Table 2
Results of Base-Line Testing, According to Treatment Group.).Response to Treatment
During the three weeks of full-dose treatment, the average change in the frequency of chest pain from the placebo phase was a reduction of 52 ±25 percent for the patients in the imipramine group (from 88 ±108 episodes during the preceding three weeks of the placebo phase); all 20 patients in this group reported a reduction in the frequency of chest pain. There was a reduction of 39 ±51 percent in the clonidine group (from 63 ±62 episodes during the placebo phase), with 15 of the 20 patients in this group reporting a reduction in the frequency of chest pain. In contrast, the average change in the frequency of chest pain in the placebo group, as compared with the corresponding three weeks of the placebo phase, was a reduction of 1 ±86 percent (from 54 ±45 episodes), with 14 of 20 patients reporting a reduction. The reduction in the frequency of chest pain in the imipramine group was significantly greater than the response in the placebo group (P = 0.03).
Although there were more women than men in the imipramine group (16 vs. 4), the proportion of women was not significantly different from that in the clonidine and placebo groups, and the response of women and men to imipramine was similar, with women reporting a 53 ±25 percent reduction and men reporting a 48 ±24 percent reduction in the frequency of pain. Ratings of the intensity of chest pain were significantly lower during the administration of imipramine (P = 0.001) and clonidine (P = 0.002), as compared with the placebo phase, but the difference between the treatment phase and the placebo phase in the placebo group was not significant (P = 0.31). However, the magnitude of the effects of imipramine and clonidine on the intensity of chest pain was not significantly different from that of the effects in the placebo group (P = 0.23 by analysis of variance).
Relation of Treatment Response to Results of Base-Line Testing
In all three treatment groups, there were no differences in the degree of change in the frequency of chest pain from the placebo phase to the treatment phase between patients with normal results on noninvasive cardiac or esophageal testing at base line and those with abnormal results (Figure 1Figure 1
Percent Change in the Frequency of Chest Pain from the Placebo Phase to the Treatment Phase in Patients with Abnormal and Normal Results on Base-Line Cardiac, Esophageal, and Psychiatric Testing, According to Treatment Group.). Repeat assessment of right ventricular sensitivity during treatment showed a significant reduction in the prevalence of chest pain provoked by right ventricular electrical stimulation in the imipramine group (P = 0.01), but not the clonidine or placebo group (Figure 2Figure 2Patients with Chest Pain during Right Ventricular Stimulation at Base Line and during the Treatment Phase, According to Treatment Group.).In contrast to the significant reduction in right ventricular sensitivity to pain during imipramine treatment, as compared with base line, there was no change in esophageal sensitivity to balloon distention from base line to the treatment phase, with regard to either the percentage of patients who had pain or the balloon volume required to provoke pain (Table 3Table 3
Results of Tests of Esophageal Motility and Sensitivity to Pain in Patients Who Underwent Testing Both at Base Line and during the Treatment Phase, According to Treatment Group.). Furthermore, there were no changes in the percentages of patients who had esophageal dysmotility during the treatment phase as compared with the base-line study.In the placebo group, patients with psychiatric diagnoses on base-line testing had a greater reduction in chest pain during the treatment phase than those without such diagnoses (Figure 1). Analysis of the rating scales for symptoms and function over time (at base line, during the placebo phase, and during the treatment phase) showed significant time effects for 9 of the 11 scales (Figure 3Figure 3
Ratings on Three Standardized Scales of Psychiatric Symptoms and Functional Impairment at Base Line and during the Placebo and Treatment Phases.), indicating psychiatric improvement over time, but there were no significant differences among the treatment groups.Safety and Long-Term Follow-up
During the treatment phase, side effects considered to be a consequence of treatment were reported by 15 patients in the imipramine group, 14 patients in the clonidine group, and 11 patients in the placebo group. In the imipramine group, electrocardiograms obtained at week 5 of the treatment phase showed slight but significant prolongation of the corrected QT (QTc) interval, as compared with the placebo phase, from 0.42 ±0.04 to 0.43 ±0.03 second (range of prolongation, -0.01 to 0.04 second; P = 0.02). In the three patients with bundle-branch-block patterns in this group, imipramine increased the QTc interval by 0.02, 0.01, and 0.01 second. At the relatively low dose used in this study, no patient in the imipramine group reported alterations in consciousness during treatment, which might suggest a proarrhythmic effect of the drug.
At the end of the study, 58 patients were offered long-term open-label imipramine treatment (2 patients preferred to continue to receive clonidine). After an average follow-up of 21 months (range, 9 to 33), we were able to contact 55 of these 58 patients to ascertain their current treatment regimen; 40 of 55 (73 percent) were still receiving imipramine (dose range, 50 to 150 mg per day; mode, 50 mg per day). No patient reported symptoms suggesting a proarrhythmic effect of the drug.
Discussion
Our major finding is that imipramine reduced the frequency of chest pain in patients with the syndrome of chest pain and normal coronary angiograms by approximately 50 percent. The benefit of imipramine was independent of the results of extensive cardiac, esophageal, and psychiatric testing and was observed in men as well as women. In the majority of patients in this study (87 percent), the characteristic chest pain was provoked by right ventricular electrical stimulation or infusion of adenosine; only in the imipramine group was there a significant reduction in the incidence of chest pain provoked by right ventricular electrical stimulation during the treatment phase, as compared with the base-line response. The symptomatic benefit of imipramine in our study is consistent with the results of previous placebo-controlled trials of antidepressants in the treatment of chronic pain syndromes such as painful diabetic neuropathy,42-44 postherpetic neuralgia,40,45 migraine headache,46,47 presumed esophageal pain,48 and other chronic pain syndromes49. Blockade of norepinephrine reuptake by drugs such as imipramine may enhance the inhibitory action of pain-modulating neurons that descend from the brain stem to the spinal cord50,51. Despite the benefit of the α2-adrenoreceptor agonist clonidine in other pain syndromes,52,53 the effect of clonidine on symptoms in our study was not significantly different from that of placebo.
Electrocardiography during exercise stress testing and radionuclide angiography did not identify patients who were more or less likely to respond to imipramine. Indeed, six patients in the imipramine group fulfilled the descriptive criteria for syndrome X, in that they had an apparently ischemic electrocardiographic response to exercise in association with chest pain22. The effect of imipramine on their symptoms and their sensitivity to cardiac pain was similar to that in the other 14 patients in this treatment group.
Esophageal dysmotility is reportedly common in patients with chest pain and normal coronary angiograms14,15,17,25. However, esophageal-motility testing in our study did not identify patients who were more or less likely to respond to imipramine. Furthermore, there were no significant differences among the three treatment groups with regard to the prevalence of esophageal dysmotility or pain in response to balloon distention between base-line testing and repeat testing during the treatment phase.
A high prevalence of psychiatric disorders has been reported in several studies of patients who have chest pain despite normal coronary angiograms,10-13 and panic disorder is a particularly common finding11,13. However, the patients in our study who had psychiatric disorders at base line were no more likely to have exaggerated sensitivity to cardiac or esophageal pain than patients without psychiatric disorders. Furthermore, patients with psychiatric disorders at base line who were treated with imipramine or clonidine were no more likely to have a reduction in the frequency of chest pain than patients without psychiatric disorders. Serial assessment with psychiatric rating scales during the study generally showed psychiatric improvement over time, regardless of treatment.
In our study, the reduction in sensitivity to cardiac pain among patients who received imipramine suggests that this drug may have a visceral analgesic effect, at the dose used in this study, that is unrelated to changes in esophageal motility or to the psychiatric profile. Although imipramine in doses used to treat depression has been associated with electrophysiologic effects similar to those of class I antiarrhythmic drugs,54 at the relatively low dose used in this study the effect of imipramine on the repolarization pattern of the electrocardiogram was minimal. Moreover, the absence of side effects suggestive of a proarrhythmic effect of imipramine during the study and an average follow-up period of almost two years indicate that the drug is safe at this dose in patients with structurally normal hearts. Because the symptomatic benefit of imipramine was independent of the results of cardiac, esophageal, or psychiatric testing before treatment, this drug may have wide applicability in the management of chest pain in patients with normal coronary angiograms who continue to have symptoms despite reassurance that their prognosis is good.
Presented in part at the 57th Scientific Meeting, American College of Gastroenterology, Miami Beach, Fla., October 26, 1992, and at the 42nd Scientific Session, American College of Cardiology, Anaheim, Calif., March 18, 1993.
Source Information
From the Cardiology Branch (R.O.C., A.A.Q., R.M., A.M.S.) and the Biostatistics Research Branch (M.A.W.), National Heart, Lung, and Blood Institute; the Neurobiology and Anesthesiology Branch, National Institute of Dental Research (R.H.G, W.B.S.); and the Section on Anxiety and Affective Disorders, National Institute of Mental Health (M.F.G., B.C.B., T.W.U.) -- all at the National Institutes of Health, Bethesda, Md.; and the Division of Gastroenterology, Georgetown University Hospital, Washington, D.C. (K.M., S.B.B.).
Address reprint requests to Dr. Cannon at Bldg. 10, Rm. 7B-15, National Institutes of Health, Bethesda, MD 20892.
- References
References
1
Proudfit WL ,Shirey EK ,Sones FM Jr . Selective cine coronary arteriography: correlation with clinical findings in 1,000 patients. Circulation 1966;33:901-910
Web of Science | Medline2
Kemp HG Jr ,Vokonas PS ,Cohn PF ,Gorlin R . The anginal syndrome associated with normal coronary arteriograms: report of a six year experience. Am J Med 1973;54:735-742
CrossRef | Web of Science | Medline3
Pasternak RC ,Thibault GE ,Savoia M ,DeSanctis RW ,Hutter AM Jr . Chest pain with angiographically insignificant coronary arterial obstruction: clinical presentation and long-term follow-up. Am J Med 1980;68:813-817
CrossRef | Web of Science | Medline4
Dart AM ,Davies HA ,Dalal J ,Ruttley M ,Henderson AH . `Angina' and normal coronary arteriograms: a follow-up study. Eur Heart J 1980;1:97-100
Medline5
Papanicolaou MN ,Califf RM ,Hlatky MA , et al. Prognostic implications of angiographically normal and insignificantly narrowed coronary arteries. Am J Cardiol 1986;58:1181-1187
CrossRef | Web of Science | Medline6
Kemp HG ,Kronmal RA ,Vlietstra RE ,Frye RL . Seven year survival of patients with normal or near normal coronary arteriograms: a CASS registry study. J Am Coll Cardiol 1986;7:479-483
CrossRef | Web of Science | Medline7
Day LJ ,Sowton E . Clinical features and follow-up of patients with angina and normal coronary arteries. Lancet 1976;2:334-337
CrossRef | Web of Science | Medline8
Ockene IS ,Shay MJ ,Alpert JS ,Weiner BH ,Dalen JE . Unexplained chest pain in patients with normal coronary arteriograms: a follow-up study of functional status. N Engl J Med 1980;303:1249-1252
Full Text | Web of Science | Medline9
Isner JM ,Salem DN ,Banas JS Jr ,Levine HJ . Long-term clinical course of patients with normal coronary arteriography: follow-up study of 121 patients with normal or nearly normal coronary arteriograms. Am Heart J 1981;102:645-653
CrossRef | Web of Science | Medline10
Bass C ,Cawley R ,Wade C , et al. Unexplained breathlessness and psychiatric morbidity in patients with normal and abnormal coronary arteries. Lancet 1983;1:605-609
CrossRef | Web of Science | Medline11
Katon W ,Hall ML ,Russo J , et al. Chest pain: relationship of psychiatric illness to coronary arteriographic results. Am J Med 1988;84:1-9
CrossRef | Web of Science | Medline12
Lantinga LJ ,Sprafkin RP ,McCroskery JH ,Baker MT ,Warner RA ,Hill NE . One-year psychosocial follow-up of patients with chest pain and angiographically normal coronary arteries. Am J Cardiol 1988;62:209-213
CrossRef | Web of Science | Medline13
Beitman BD ,Mukerji V ,Lamberti JW , et al. Panic disorder in patients with chest pain and angiographically normal coronary arteries. Am J Cardiol 1989;63:1399-1403
CrossRef | Web of Science | Medline14
Brand DL ,Martin D ,Pope CE II . Esophageal manometrics in patients with angina-like chest pain. Am J Dig Dis 1977;22:300-304
CrossRef | Medline15
Traube M ,Albibi R ,McCallum RW . High-amplitude peristaltic esophageal contractions associated with chest pain. JAMA 1983;250:2655-2659
CrossRef | Web of Science | Medline16
Janssens J ,Vantrappen G ,Ghillebert G . 24-Hour recording of esophageal pressure and pH in patients with noncardiac chest pain. Gastroenterology 1986;90:1978-1984
Web of Science | Medline17
Richter JE ,Bradley LA ,Castell DO . Esophageal chest pain: current controversies in pathogenesis, diagnosis, and therapy. Ann Intern Med 1989;110:66-78
Web of Science | Medline18
Opherk D ,Zebe H ,Weihe E , et al. Reduced coronary dilatory capacity and ultrastructural changes of the myocardium in patients with angina pectoris but normal coronary arteriograms. Circulation 1981;63:817-825
CrossRef | Web of Science | Medline19
Cannon RO III ,Watson RM ,Rosing DR ,Epstein SE . Angina caused by reduced vasodilator reserve of the small coronary arteries. J Am Coll Cardiol 1983;1:1359-1373
CrossRef | Web of Science | Medline20
Legrand V ,Hodgson JM ,Bates ER , et al. Abnormal coronary flow reserve and abnormal radionuclide exercise test results in patients with normal coronary angiograms. J Am Coll Cardiol 1985;6:1245-1253
CrossRef | Web of Science | Medline21
Greenberg MA ,Grose RM ,Neuburger N ,Silverman R ,Strain JE ,Cohen MV . Impaired coronary vasodilator responsiveness as a cause of lactate production during pacing-induced ischemia in patients with angina pectoris and normal coronary arteries. J Am Coll Cardiol 1987;9:743-751
CrossRef | Web of Science | Medline22
Cannon RO III ,Camici PG ,Epstein SE . Pathophysiological dilemma of syndrome X. Circulation 1992;85:883-892
Web of Science | Medline23
Clouse RE ,Lustman PJ . Psychiatric illness and contraction abnormalities of the esophagus. N Engl J Med 1983;309:1337-1342
Full Text | Web of Science | Medline24
Roy-Byrne PP ,Schmidt P ,Cannon RO ,Diem H ,Rubinow DR . Microvascular angina and panic disorder. Int J Psychiatry Med 1989;19:315-325
CrossRef | Web of Science | Medline25
Cannon RO III ,Cattau EL Jr ,Yakshe PN , et al. Coronary flow reserve, esophageal motility, and chest pain in patients with angiographically normal coronary arteries. Am J Med 1990;88:217-222
CrossRef | Web of Science | Medline26
Shapiro LM ,Crake T ,Poole-Wilson PA . Is altered cardiac sensation responsible for chest pain in patients with normal coronary arteries? Clinical observation during cardiac catheterization. BMJ 1988;296:170-171
CrossRef | Web of Science | Medline27
Cannon RO III ,Quyyumi AA ,Schenke WH , et al. Abnormal cardiac sensitivity in patients with chest pain and normal coronary arteries. J Am Coll Cardiol 1990;16:1359-1366
CrossRef | Web of Science | Medline28
Lagerqvist B ,Sylven C ,Waldenstrom A . Lower threshold for adenosine-induced chest pain in patients with angina and normal coronary angiograms. Br Heart J 1992;68:282-285
CrossRef | Web of Science | Medline29
Richter JE ,Barish CF ,Castell DO . Abnormal sensory perception in patients with esophageal chest pain. Gastroenterology 1986;91:845-852
Web of Science | Medline30
Bruce RA ,Hornsten TR . Exercise stress testing in evaluation of patients with ischemic heart disease. Prog Cardiovasc Dis 1969;11:371-390
CrossRef | Medline31
Bonow RO ,Rosing DR ,Bacharach SL , et al. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation 1981;64:787-796
CrossRef | Web of Science | Medline32
Schleyer B, Aaronson C, Mannuzza S, Martin LY, Fyer AJ. Schedule for Affective Disorders and Schizophrenia -- lifetime version (modified for the study of anxiety disorders) revised [SADS-LA(R)]. New York: New York State Psychiatric Clinic, Anxiety Disorders Clinic, 1990.
33
Mannuzza S ,Fyer AJ ,Martin LY , et al. Reliability of anxiety assessment. I. Diagnostic agreement. Arch Gen Psychiatry 1989;46:1093-1101
Web of Science | Medline34
Diagnostic and statistical manual of mental disorders: DSM-III-R. 3rd ed. rev. Washington, D.C.: American Psychiatric Press, 1987.
35
National Institute of Mental Health 36
Spielberger CD, Gorsuch RL, Lushene RE. Manual for the State-Trait Anxiety Inventory. Palo Alto, Calif.: Consulting Psychologists Press, 1970.
37
Zung WWK . A rating instrument for anxiety disorders. Psychosomatics 1971;12:371-379
Web of Science | Medline38
Bunney WE Jr ,Hamburg DA . Methods for reliable longitudinal observation of behavior. Arch Gen Psychiatry 1963;9:280-294
Web of Science | Medline39
Gracely RH ,Dubner R ,McGrath PA . Narcotic analgesia: fentanyl reduces the intensity but not the unpleasantness of painful tooth pulp sensations. Science 1979;203:1261-1263
CrossRef | Web of Science | Medline40
Max MB ,Schafer SC ,Culnane M ,Smoller B ,Dubner R ,Gracely RH . Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988;38:1427-1432
Web of Science | Medline41
SAS user's guide: statistics, version 5 ed. Cary, N.C.: SAS Institute, 1985:433-506.
42
Kvinesdal B ,Molin J ,Froland A ,Gram LF . Imipramine treatment of painful diabetic neuropathy. JAMA 1984;251:1727-1730
CrossRef | Web of Science | Medline43
Gomez-Perez FJ ,Rull JA ,Dies H ,Rodriguez-Rivera JG ,Gonzalez-Barranco J ,Lozano-Castaneda O . Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy: a double-blind cross-over study. Pain 1985;25:395-400
CrossRef | Web of Science44
Max MB ,Lynch SA ,Muir J ,Shoaf SE ,Smoller B ,Dubner R . Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-1256
Full Text | Web of Science | Medline45
Watson CP ,Evans RJ ,Reed K ,Merskey H ,Goldsmith L ,Warsh J . Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982;32:671-673
Web of Science | Medline46
Gomersall JD ,Stuart A . Amitriptyline in migraine prophylaxis: changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry 1973;36:684-690
CrossRef | Web of Science | Medline47
Couch JR ,Ziegler DK ,Hassanein R . Amitriptyline in the prophylaxis of migraine: effectiveness and relationship of antimigraine and antidepressant effects. Neurology 1976;26:121-127
Web of Science | Medline48
Clouse RE ,Lustman PJ ,Eckert TC ,Ferney DM ,Griffith LS . Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities: a double-blind, placebo-controlled trial. Gastroenterology 1987;92:1027-1036
Web of Science | Medline49
Egbunike IG ,Chaffee BJ . Antidepressants in the management of chronic pain syndromes. Pharmacotherapy 1990;10:262-270
Web of Science | Medline50
Basbaum AI ,Fields HL . Endogenous pain control mechanisms: review and hypothesis. Ann Neurol 1978;4:451-462
CrossRef | Web of Science | Medline51
Dubner R ,Bennett GJ . Spinal and trigeminal mechanisms of nociception. Annu Rev Neurosci 1983;6:381-418
CrossRef | Web of Science | Medline52
Max MB ,Schafer SC ,Culnane M ,Dubner R ,Gracely RH . Association of pain relief with drug side effects in postherpetic neuralgia: a single-dose study of clonidine, codeine, ibuprofen, and placebo. Clin Pharmacol Ther 1988;43:363-371
CrossRef | Web of Science | Medline53
Zeigler D ,Lynch SA ,Muir J ,Benjamin J ,Max MB . Transdermal clonidine versus placebo in painful diabetic neuropathy. Pain 1992;48:403-408
CrossRef | Web of Science | Medline54
Bigger JT Jr ,Giardina EGV ,Perel JM ,Kantor SJ ,Glassman AH . Cardiac antiarrhythmic effect of imipramine hydrochloride. N Engl J Med 1977;296:206-208
Full Text | Web of Science | Medline
- Citing Articles (135)
Citing Articles
1
M. Shapiro, R. Simantov, M. Yair, M. Leitman, A. Blatt, E. Scapa, E. Broide. (2012) Comparison of central and intraesophageal factors between gastroesophageal reflux disease (GERD) patients and those with GERD-related noncardiac chest pain. Diseases of the Esophagusno-no
CrossRef2
Ronnie Fass, Tiberiu Hershcovici. 2012. The Problem of Heartburn, and Atypical Chest Pain. , 17-38.
CrossRef3
T. M. T. Nguyen, G. D. Eslick. (2012) Systematic review: the treatment of noncardiac chest pain with antidepressants. Alimentary Pharmacology & Therapeuticsn/a-n/a
CrossRef4
T. Hershcovici, S. R. Achem, L. K. Jha, R. Fass. (2011) Systematic review: the treatment of noncardiac chest pain. Alimentary Pharmacology & Therapeuticsno-no
CrossRef5
Ragab A. Mahfouz, Mohamed Abdou, Ashraf Elsaeed, Nader T. Kandil. (2011) Cardiac syndrome-X: Is it benign or malignant? An Egyptian follow-up study. The Egyptian Heart Journal
CrossRef6
Nikos Viazis, Anastasia Keyoglou, Alexandros K Kanellopoulos, George Karamanolis, John Vlachogiannakos, Konstantinos Triantafyllou, Spiros D Ladas, Dimitrios G Karamanolis. (2011) Selective Serotonin Reuptake Inhibitors for the Treatment of Hypersensitive Esophagus: A Randomized, Double-Blind, Placebo-Controlled Study. The American Journal of Gastroenterology
CrossRef7
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 57:19, e215-e367
CrossRef8
Mark R. Vesely, Vasken Dilsizian. (2011) Microvascular Angina: Assessment of Coronary Blood Flow, Flow Reserve, and Metabolism. Current Cardiology Reports 13:2, 151-158
CrossRef9
Amindra S. Arora, David A. Katzka. (2011) How Do I Handle the Patient With Noncardiac Chest Pain?. Clinical Gastroenterology and Hepatology 9:4, 295-304
CrossRef10
Francis J. Keefe, Rebecca A. Shelby, Tamara J. Somers, Indira Varia, Michael Blazing, Sandra J. Waters, Daphne McKee, Susan Silva, Lelin She, James A. Blumenthal, John O’Connor, Verena Knowles, Paige Johnson, Lawrence Bradley. (2011) Effects of coping skills training and sertraline in patients with non-cardiac chest pain: A randomized controlled study. PAIN 152:4, 730-741
CrossRef11
E. A. Asbury, C. M. Webb, P. Collins. (2011) Group support to improve psychosocial well-being and primary-care demands among women with cardiac syndrome X. Climacteric 14:1, 100-104
CrossRef12
Christian Lottrup, Søren Schou Olesen, Asbjørn Mohr Drewes. (2011) The Pain System in Oesophageal Disorders: Mechanisms, Clinical Characteristics, and Treatment. Gastroenterology Research and Practice 2011, 1-14
CrossRef13
Manu R. Sood, Colin D. Rudolph. 2011. Achalasia and Other Motor Disorders. , 248-254.
CrossRef14
Lynn Nugent, Puja K. Mehta, C. Noel Bairey Merz. (2011) Gender and microvascular angina. Journal of Thrombosis and Thrombolysis 31:1, 37-46
CrossRef15
Jose M. Remes-Troche. (2010) The Hypersensitive Esophagus: Pathophysiology, Evaluation, and Treatment Options. Current Gastroenterology Reports 12:5, 417-426
CrossRef16
Kenneth R. DeVault. 2010. Esophageal Motility Disorders. , 256-266.
CrossRef17
Jason R Roberts, Marcelo F Vela, Joel E Richter. 2010. Esophageal Motility Disorders: Achalasia and Spastic Motor Disorders. , 78-92.
CrossRef18
Philip Spinhoven, A.J. Willem Van der Does, Eduard Van Dijk, Yanda R. Van Rood. (2010) Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine. Journal of Psychosomatic Research 69:3, 227-235
CrossRef19
Arang Samim, Lynn Nugent, Puja K. Mehta, Chrisandra Shufelt, C. Noel Bairey Merz. (2010) Treatment of Angina and Microvascular Coronary Dysfunction. Current Treatment Options in Cardiovascular Medicine 12:4, 355-364
CrossRef20
Evan S. Dellon, Nicholas J. Shaheen. (2010) Persistent Reflux Symptoms in the Proton Pump Inhibitor Era: The Changing Face of Gastroesophageal Reflux Disease. Gastroenterology 139:1, 7-13.e3
CrossRef21
Hyuk Lee, Jeong Hwan Kim, Byung-Hoon Min, Jun Haeng Lee, Hee Jung Son, Jae J Kim, Jong Chul Rhee, Young Ju Suh, Seonwoo Kim, Poong-Lyul Rhee. (2010) Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. The American Journal of Gastroenterology 105:7, 1504-1512
CrossRef22
C. Noel Bairey Merz, Marian B. Olson, Candace McClure, Yu-Ching Yang, James Symons, George Sopko, Sheryl F. Kelsey, Eileen Handberg, B. Delia Johnson, Rhonda M. Cooper-DeHoff, Barry Sharaf, William J. Rogers, Carl J. Pepine. (2010) A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: Results from the National Institutes of Health/National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation (WISE). American Heart Journal 159:6, 987.e1-987.e7
CrossRef23
J. A. Panza. (2010) Coronary atherosclerosis: extending to the microcirculation?. European Heart Journal 31:8, 905-907
CrossRef24
Kamila S. White. (2010) Assessment and Treatment of Psychological Causes of Chest Pain. Medical Clinics of North America 94:2, 291-318
CrossRef25
Su Jin Hong. (2010) Diagnosis and Management of Esophageal Chest Pain. The Korean Journal of Gastroenterology 55:4, 217
CrossRef26
Amit Agrawal, Donald O. Castell. 2010. Esophageal Causes of Chest Pain. , 20-26.
CrossRef27
Richard O. Cannon. (2009) Microvascular Angina and the Continuing Dilemma of Chest Pain With Normal Coronary Angiograms. Journal of the American College of Cardiology 54:10, 877-885
CrossRef28
Tiong K. Lim, AnnaMaria J Choy, Faisel Khan, Jill JF Belch, Allan D Struthers, Chim C Lang. (2009) Therapeutic Development in Cardiac Syndrome X: A Need to Target the Underlying Pathophysiology. Cardiovascular Therapeutics 27:1, 49-58
CrossRef29
John F. Beltrame, Filippo Crea, Paolo Camici. (2009) Advances in Coronary Microvascular Dysfunction. Heart, Lung and Circulation 18:1, 19-27
CrossRef30
Elizabeth A. Asbury, Nasim Kanji, Edzard Ernst, Mahmoud Barbir, Peter Collins. (2009) Autogenic training to manage symptomology in women with chest pain and normal coronary arteries. Menopause 16:1, 60-65
CrossRef31
Ronnie Fass. (2009) Functional Heartburn: What It Is and How to Treat It. Gastrointestinal Endoscopy Clinics of North America 19:1, 23-33
CrossRef32
Sami R. Achem. (2008) Noncardiac Chest Pain–Treatment Approaches. Gastroenterology Clinics of North America 37:4, 859-878
CrossRef33
Sami R. Achem. (2008) Treatment of Non-Cardiac Chest Pain. Disease-a-Month 54:9, 642-670
CrossRef34
Paul R. Slobodny. (2008) Cardiac Syndrome X. Dimensions of Critical Care Nursing 27:5, 209-212
CrossRef35
Ernest P. Bouras, Nicholas J. Talley, Michael Camilleri, Duane D. Burton, Michael G. Heckman, Julia E. Crook, Elliott Richelson. (2008) Effects of Amitriptyline on Gastric Sensorimotor Function and Postprandial Symptoms in Healthy Individuals: A Randomized, Double-Blind, Placebo-Controlled Trial. The American Journal of Gastroenterology 103:8, 2043-2050
CrossRef36
Brian E. Lacy, Kirsten Weiser. (2008) Esophageal Motility Disorders. Journal of Clinical Gastroenterology 42:5, 652-658
CrossRef37
Elizabeth A. Asbury, Colin Slattery, Amanda Grant, Lynda Evans, Mahmoud Barbir, Peter Collins. (2008) Cardiac rehabilitation for the treatment of women with chest pain and normal coronary arteries. Menopause 15:3, 454-460
CrossRef38
Ronnie Fass, Tomás Navarro-Rodriguez. (2008) Noncardiac Chest Pain. Journal of Clinical Gastroenterology 42:5, 636-646
CrossRef39
r. s. choung, f. cremonini, p. thapa, a. r. zinsmeister, n. j. talley. (2008) The effect of short-term, low-dose tricyclic and tetracyclic antidepressant treatment on satiation, postnutrient load gastrointestinal symptoms and gastric emptying: a double-blind, randomized, placebo-controlled trial. Neurogastroenterology & Motility 20:3, 220-227
CrossRef40
C. Shekhar, P. J. Whorwell. (2008) Evaluation and Management of Patients with Noncardiac Chest Pain. Gastroenterology Research and Practice 2008, 1-4
CrossRef41
M. Valkamo, J. Hintikka, L. Niskanen, H. Viinamäki. (2008) Psychiatric morbidity and the presence and absence of angiographic coronary disease in patients with chest pain. Acta Psychiatrica Scandinavica 104:5, 391
CrossRef42
Albert J. Bellg. 2007. Cardiovascular Disease. , 125-152.
CrossRef43
G. Cocco, D. Chu. (2007) Stress-induced cardiomyopathy: A review. European Journal of Internal Medicine 18:5, 369-379
CrossRef44
Daniel Sifrim, Fernando Fornari. (2007) Non-achalasic motor disorders of the oesophagus. Best Practice & Research Clinical Gastroenterology 21:4, 575-593
CrossRef45
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliot M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction—Executive Summary. Journal of the American College of Cardiology 50:7, 652-726
CrossRef46
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliott M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:7, e1-e157
CrossRef47
Johan Ormel, Michael Von Korff, Huibert Burger, Kate Scott, Koen Demyttenaere, Yue-qin Huang, José Posada-Villa, Jean Pierre Lepine, Matthias C. Angermeyer, Daphna Levinson, Giovanni de Girolamo, Norito Kawakami, Elie Karam, María Elena Medina-Mora, Oye Gureje, David Williams, Josep Maria Haro, Evelyn J. Bromet, Jordi Alonso, Ron Kessler. (2007) Mental disorders among persons with heart disease — results from World Mental Health surveys. General Hospital Psychiatry 29:4, 325-334
CrossRef48
Ronnie Fass. (2007) Functional heartburn. Current GERD Reports 1:2, 93-98
CrossRef49
Sami R. Achem. (2007) New Frontiers for the Treatment of Noncardiac Chest Pain: The Adenosine Receptors. The American Journal of Gastroenterology 102:5, 939-941
CrossRef50
Gregory S. Sayuk, Ray E. Clouse. (2007) Esophageal symptoms following antireflux surgery: Issues and management. Current GERD Reports 1:1, 41-49
CrossRef51
Christian Albus, Christoph Herrmann-Lingen. (2007) Funktionelle Störungen in der Kardiologie. Psychosomatik und Konsiliarpsychiatrie 1:2, 118-122
CrossRef52
Ting K Cheung, Benjamin CY Wong. (2006) Proton-pump inhibitor failure/resistance: Proposed mechanisms and therapeutic algorithm. Journal of Gastroenterology and Hepatology 21:s5, S119-S124
CrossRef53
V. Ortiz Bellver, V. Garrigues Gil. (2006) Aproximación al dolor torácico desde el punto de vista del digestólogo. Gastroenterología y Hepatología 29:8, 455-461
CrossRef54
Kevin W. Olden. (2006) Treatment of noncardiac chest pain of psychological origin. Current Treatment Options in Gastroenterology 9:1, 51-58
CrossRef55
D. BROEKAERT, B. FISCHLER, D. SIFRIM, J. JANSSENS, J. TACK. (2006) Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. Alimentary Pharmacology and Therapeutics 23:3, 365-370
CrossRef56
Daniela Husser, Andreas Bollmann, Christian Kühne, Jochen Molling, Helmut U. Klein. (2006) Evaluation of noncardiac chest pain: diagnostic approach, coping strategies and quality of life. European Journal of Pain 10:1, 51-55
CrossRef57
Wai-Man Wong, Sara Risner-Adler, Joy Beeler, Sara Habib, Jimmy Bautista, Steven Goldman, Ronnie Fass. (2005) Noncardiac Chest Pain. Journal of Clinical Gastroenterology 39:10, 858-862
CrossRef58
M. Bixquert-Jiménez, L. Bixquert-Pla. (2005) Tratamiento con antidepresivos en los trastornos funcionales digestivos. Gastroenterología y Hepatología 28:8, 485-492
CrossRef59
Jennifer How, Georg Volz, Simon Doe, Carol Heycock, Jennifer Hamilton, Clive Kelly. (2005) The causes of musculoskeletal chest pain in patients admitted to hospital with suspected myocardial infarction. European Journal of Internal Medicine 16:6, 432-436
CrossRef60
Guy D Eslick, David S Coulshed, Nicholas J Talley. (2005) Diagnosis and treatment of noncardiac chest pain. Nature Clinical Practice Gastroenterology & Hepatology 2:10, 463-472
CrossRef61
E. A. Asbury, P. Collins. (2005) Cardiac syndrome X. International Journal of Clinical Practice 59:9, 1063-1069
CrossRef62
Amit Rastogi, Adam Slivka, Arthur James Moser, Arnold Wald. (2005) Controversies Concerning Pathophysiology and Management of Acalculous Biliary-Type Abdominal Pain. Digestive Diseases and Sciences 50:8, 1391-1401
CrossRef63
Ram Dickman, Ronnie Fass. (2005) Functional heartburn. Current Treatment Options in Gastroenterology 8:4, 285-291
CrossRef64
Gregory S. Sayuk, Ray E. Clouse. (2005) Management of esophageal symptoms following fundoplication. Current Treatment Options in Gastroenterology 8:4, 293-303
CrossRef65
Premjit S Chahal, Satish S. C Rao. (2005) Functional Chest Pain. Journal of Clinical Gastroenterology 39:Supplement 3, S204-S209
CrossRef66
Arnold Wald. (2005) Functional Biliary-Type Pain. Journal of Clinical Gastroenterology 39:Supplement 3, S217-S222
CrossRef67
Wai-Man Wong, Joy Beeler, Sara Risner-Adler, Sara Habib, Jimmy Bautista, Ronnie Fass. (2005) Attitudes and Referral Patterns of Primary Care Physicians When Evaluating Subjects with Noncardiac Chest Pain?A National Survey. Digestive Diseases and Sciences 50:4, 656-661
CrossRef68
C. Manterola, M. S. Barroso, H. Losada, S. Munoz, M. Vial. (2004) Prevalence of esophageal disorders in patients with recurrent chest pain*. Diseases of the Esophagus 17:4, 285-291
CrossRef69
Ronnie Fass. (2004) Sensory Testing of the Esophagus. Journal of Clinical Gastroenterology 38:8, 628-641
CrossRef70
WAI-MAN WONG, RONNIE FASS. (2004) Extraesophageal and atypical manifestations of GERD. Journal of Gastroenterology and Hepatology 19:s3, S33-S43
CrossRef71
Filippo Cremonini, Silvia Delgado-Aros, Nicholas J. Talley. (2004) Functional dyspepsia: drugs for new (and old) therapeutic targets. Best Practice & Research Clinical Gastroenterology 18:4, 717-733
CrossRef72
Wai-Man Wong, Ronnie Fass. (2004) Noncardiac chest pain. Current Treatment Options in Gastroenterology 7:4, 273-278
CrossRef73
G. Sarnelli, J. Vandenberghe, J. Tack. (2004) Visceral hypersensitivity in functional disorders of the upper gastrointestinal tract. Digestive and Liver Disease 36:6, 371-376
CrossRef74
M. W. Ketterer. (2004) What's "Unstable" in Unstable Angina?. Psychosomatics 45:3, 185-196
CrossRef75
Wai-Man Wong, Benjamin Chun-Yu Wong. (2004) Noncardiac chest pain: an Asian view. Gastroenterology Clinics of North America 33:1, 125-133
CrossRef76
Max J. Schmulson, Miguel Angel Valdovinos. (2004) Current and future treatment of chest pain of presumed esophageal origin. Gastroenterology Clinics of North America 33:1, 93-105
CrossRef77
Sami R Achem. (2004) Treatment of spastic esophageal motility disorders. Gastroenterology Clinics of North America 33:1, 107-124
CrossRef78
Kevin W. Olden. (2004) The psychological aspects of noncardiac chest pain. Gastroenterology Clinics of North America 33:1, 61-67
CrossRef79
Hazar Michael, Robert S. Fisher. (2004) Treatment of epiphrenic and mid-esophageal diverticula. Current Treatment Options in Gastroenterology 7:1, 41-52
CrossRef80
Gary W. Falk. 2004. Chest Pain, Non-Cardiac. , 295-299.
CrossRef81
M. Borjesson, P. Rolny, C. Mannheimer, M. Pilhall. (2003) Nutcracker oesophagus: a double-blind, placebo-controlled, cross-over study of the effects of lansoprazole. Alimentary Pharmacology and Therapeutics 18:11-12, 1129-1135
CrossRef82
Roy Dekel, Ronnie Fass. (2003) Current perspectives on the diagnosis and treatment of functional esophageal disorders. Current Gastroenterology Reports 5:4, 314-322
CrossRef83
William L Hasler. (2003) Pharmacotherapy for intestinal motor and sensory disorders. Gastroenterology Clinics of North America 32:2, 707-732
CrossRef84
Guy D Eslick, Ronnie Fass. (2003) Noncardiac chest pain: evaluation and treatment. Gastroenterology Clinics of North America 32:2, 531-552
CrossRef85
Nicolas J. Talley. (2003) SSRIs in IBS: Sensing a dash of disappointment. Clinical Gastroenterology and Hepatology 1:3, 155-159
CrossRef86
Sjoerd D. Kuiken, Guido N.J. Tytgat, Guy E.E. Boeckxstaens. (2003) The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: A double blind, randomized, placebo-controlled study. Clinical Gastroenterology and Hepatology 1:3, 219-228
CrossRef87
U Ladabaum, D Glidden. (2002) Effect of the selective serotonin reuptake inhibitor sertraline on gastric sensitivity and compliance in healthy humans1. Neurogastroenterology and Motility 14:4, 395-402
CrossRef88
Arnold Wald. (2002) Psychotropic Agents in Irritable Bowel Syndrome. Journal of Clinical Gastroenterology 35:Supplement, S53-S57
CrossRef89
W.-M. Wong, K. C. Lai, C. P. Lau, W. H. C. Hu, W. H. Chen, B. C. Y. Wong, W. M. Hui, Y. H. Wong, H. H. X. Xia, S. K. Lam. (2002) Upper gastrointestinal evaluation of Chinese patients with non-cardiac chest pain. Alimentary Pharmacology and Therapeutics 16:3, 465-471
CrossRef90
Raija Tyni-Lenne, Signe Stryjan, Björn Eriksson, Margareta Berglund, Christer Sylven. (2002) Beneficial therapeutic effects of physical training and relaxation therapy in women with coronary syndrome X. Physiotherapy Research International 7:1, 35-43
CrossRef91
Michael A Pezzone, Arnold Wald. (2002) Functional bowel disorders in inflammatory bowel disease. Gastroenterology Clinics of North America 31:1, 347-357
CrossRef92
V. Alin Botoman. (2002) Noncardiac Chest Pain. Journal of Clinical Gastroenterology 34:1, 6-14
CrossRef93
M. Valkamo, J. Hintikka, L. Niskanen, H. Viinamaki. (2001) Psychiatric morbidity and the presence and absence of angiographic coronary disease in patients with chest pain. Acta Psychiatrica Scandinavica 104:5, 391-396
CrossRef94
Peter Holzer. (2001) Gastrointestinal afferents as targets of novel drugs for the treatment of functional bowel disorders and visceral pain. European Journal of Pharmacology 429:1-3, 177-193
CrossRef95
Joel E Richter. (2001) Oesophageal motility disorders. The Lancet 358:9284, 823-828
CrossRef96
Rebecca C. Thurston, Francis J. Keefe, Laurence Bradley, K.Ranga Rama Krishnan, David S. Caldwell. (2001) Chest pain in the absence of coronary artery disease: a biopsychosocial perspective. Pain 93:2, 95-100
CrossRef97
Jassim Al Suwaidi, Stuart T. Higano, David R. Holmes, Amir Lerman. (2001) Pathophysiology, Diagnosis, and Current Management Strategies for Chest Pain in Patients With Normal Findings on Angiography. Mayo Clinic Proceedings 76:8, 813-822
CrossRef98
J Al Suwaidi, S T Higano, D R Holmes, A Lerman. (2001) Pathophysiology, diagnosis, and current management strategies for chest pain in patients with normal findings on angiography.. Mayo Clinic Proceedings 76:8, 813-822
CrossRef99
Dawn L. Adamson, Carolyn M. Webb, Peter Collins. (2001) Esterified estrogens combined with methyltestosterone improve emotional well-being in postmenopausal women with chest pain and normal coronary angiograms. Menopause 8:4, 233-238
CrossRef100
Björn E Eriksson, Raija Tyni-Lennè, Jan Svedenhag, Rolf Hallin, Kerstin Jensen-Urstad, Mats Jensen-Urstad, Kristina Bergman, Christer Sylvén. (2000) Physical training in Syndrome X. Journal of the American College of Cardiology 36:5, 1619-1625
CrossRef101
Eugene Braunwald, Elliott M Antman, John W Beasley, Robert M Califf, Melvin D Cheitlin, Judith S Hochman, Robert H Jones, Dean Kereiakes, Joel Kupersmith, Thomas N Levin, Carl J Pepine, John W Schaeffer, Earl E Smith, David E Steward, Pierre Theroux, Raymond J Gibbons, Joseph S Alpert, Kim A Eagle, David P Faxon, Valentin Fuster, Timothy J Gardner, Gabriel Gregoratos, Richard O Russell, Sidney C Smith. (2000) ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarction. Journal of the American College of Cardiology 36:3, 970-1062
CrossRef102
Ashok Beedassy, Philip O. Katz, Antonio Gruber, Paolo L. Peghini, Donald O. Castell. (2000) Prior Sensitization of Esophageal Mucosa by Acid Reflux Predisposes to Reflux-induced Chest Pain. Journal of Clinical Gastroenterology 31:2, 121-124
CrossRef103
Kevin W. Olden, Douglas A. Drossman. (2000) PSYCHOLOGIC AND PSYCHIATRIC ASPECTS OF GASTROINTESTINAL DISEASE. Medical Clinics of North America 84:5, 1313-1327
CrossRef104
Joel E. Richter. (2000) Noncardiac (unexplained) chest pain. Current Treatment Options in Gastroenterology 3:4, 329-334
CrossRef105
Philip O. Katz. (2000) Chest pain of esophageal origin. Current Opinion in Gastroenterology 16:4, 369-373
CrossRef106
Sami R. Achem, Kenneth R. Vault. (2000) Recent developments in chest pain of undetermined origin. Current Gastroenterology Reports 2:3, 201-209
CrossRef107
Jassim Al Suwaidi, Amir Lerman. (2000) Syndrome X. Current Treatment Options in Cardiovascular Medicine 2:1, 73-82
CrossRef108
David Fishbain. (2000) Evidence-based data on pain relief with antidepressants. Annals of Medicine 32:5, 305-316
CrossRef109
Storr, Allescher. (1999) Esophageal pharmacology and treatment of primary motility disorders. Diseases of the Esophagus 12:4, 241-257
CrossRef110
Chandra Prakash, Ray E. Clouse. (1999) Cyclic vomiting syndrome in adults: clinical features and response to tricyclic antidepressants. The American Journal of Gastroenterology 94:10, 2855-2860
CrossRef111
S Wessely, C Nimnuan, M Sharpe. (1999) Functional somatic syndromes: one or many?. The Lancet 354:9182, 936-939
CrossRef112
Yehuda Ringel, Douglas A. Drossman. (1999) Treatment of Patients with Functional Esophageal Symptoms. Journal of Clinical Gastroenterology 28:3, 189-193
CrossRef113
Felipe Atienza, José A. Velasco, Francisco Ridocci, Sue Brown, Juan Carlos Kaski. (1999) Assessment of quality of life in patients with chest pain and normal coronary arteriogram (syndrome x) using a specific questionnaire. Clinical Cardiology 22:4, 283-291
CrossRef114
(1999) Atypical chest pain patients: A comparison with ischaemic heart disease and control patients. Nordic Journal of Psychiatry 53:3, 191-195
CrossRef115
Arnold Wald. (1999) Irritable bowel syndrome. Current Treatment Options in Gastroenterology 2:1, 13-19
CrossRef116
Aydamir Alrakawi, Ray E. Clouse. (1998) The changing use of esophageal manometry in clinical practice. The American Journal of Gastroenterology 93:12, 2359-2362
CrossRef117
Kenneth R. DeVault, Sami R. Achem. (1998) Noncardiac chest pain of esophageal origin. Current Treatment Options in Gastroenterology 1:1, 49-55
CrossRef118
D Hasdai, D R Holmes, S T Higano, J C Burnett, A Lerman. (1998) Prevalence of coronary blood flow reserve abnormalities among patients with nonobstructive coronary artery disease and chest pain.. Mayo Clinic Proceedings 73:12, 1133-1140
CrossRef119
Josef Finsterer, Claudia Stöllberger, Günther Ernst. (1998) Chest pain in cardiac syndrome X-caused by neuromuscular disorders?. Herz 23:5, 303-306
CrossRef120
H. Mertz, R. Fass, A. Kodner, F. Yan-Go, S. Fullerton, E. A. Mayer. (1998) Effect of Amitryptiline on Symptoms, Sleep, and Visceral Perception in Patients With Functional Dyspepsia. The American Journal of Gastroenterology 93:2, 160-165
CrossRef121
Vincenzo Pasceri, Gaetano A Lanza, Antonino Buffon, Annibale S Montenero, Filippo Crea, Attilio Maseri. (1998) Role of Abnormal Pain Sensitivity and Behavioral Factors in Determining Chest Pain in Syndrome X. Journal of the American College of Cardiology 31:1, 62-66
CrossRef122
John M. Wo, J. Patrick Waring. (1997) MEDICAL THERAPY OF GASTROESOPHAGEAL REFLUX AND MANAGEMENT OF ESOPHAGEAL STRICTURES. Surgical Clinics of North America 77:5, 1041-1062
CrossRef123
Rollin M. Gallagher, Elias Pasol. (1997) Psychopharmacologic drugs in chronic pain syndromes. Current Pain and Headache Reports 1:2, 137-152
CrossRef124
Richard P. Fleet, Gilles Dupuis, André Marchand, Denis Burelle, Bernard D. Beitman. (1997) Detecting panic disorder in emergency department chest pain patients: A validated model to improve recognition. Annals of Behavioral Medicine 19:2, 124-131
CrossRef125
Mark A. Lumley, Tracey Torosian, Mark W. Ketterer, Sol D. Pickard. (1997) Psychosocial Factors Related to Noncardiac Chest Pain During Treadmill Exercise. Psychosomatics 38:3, 230-238
CrossRef126
Richard P. Fleet, Bernard D. Beitman. (1997) Unexplained chest pain: When is it panic disorder?. Clinical Cardiology 20:3, 187-194
CrossRef127
Michael J Tueth. (1997) Managing recurrent nonischemic chest pain in the emergency department. The American Journal of Emergency Medicine 15:2, 170-172
CrossRef128
Susan Gross Fisher, Richard Cooper, Laura Weber, Youlian Liao. (1997) Psychosocial Correlates of Chest Pain Among African-American Women. Women & Health 24:3, 19-35
CrossRef129
Julio A Panza, Joy M Laurienzo, Rodolfo V Curiel, Ellis F Unger, Arshed A Quyyumi, Vasken Dilsizian, Richard O Cannon. (1997) Investigation of the Mechanism of Chest Pain in Patients With Angiographically Normal Coronary Arteries Using Transesophageal Dobutamine Stress Echocardiography. Journal of the American College of Cardiology 29:2, 293-301
CrossRef130
Ray E. Clouse. (1997) Pharmacotherapy of Altered Brain-Gut Interactions in Functional Gastrointestinal Disorders. Journal of Pediatric Gastroenterology & Nutrition 25, 18
CrossRef131
Mark W. Ketterer, James Brymer, Ken Rhoads, Phillip Kraft, Lori Kenyon, Barb Foley, William R. Lovallo, C. J. Voight. (1996) Emotional distress among males with “Syndrome X”. Journal of Behavioral Medicine 19:5, 455-466
CrossRef132
Albert Gjedde. (1996) PET criteria of cerebral tissue viability in ischema. Acta Neurologica Scandinavica 93, 3-5
CrossRef133
A. F. Allaz, J. Desmeules, V. Piguet. (1995) Douleurs thoraciques fonctionnelles. Douleur et Analgésie 8:3, 83-85
CrossRef134
Scott R. Brazer, Jane E. Onken, Christine B. Dalton, Judy W. Smith, Susan S. Schiffman. (1995) Effect of different coffees on esophageal acid contact time and symptoms in coffee-sensitive subjects. Physiology & Behavior 57:3, 563-567
CrossRef135
(1994) Imipramine in Patients with Chest Pain Despite Normal Coronary Angiograms. New England Journal of Medicine 331:13, 882-883
Full Text
- Letters
